
POLICY DETERMINATION



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

***Current Policy Effective Date: 7/1/25**
(See policy history boxes for previous effective dates)

Title: 90382-Respiratory Syncytial Virus (Clestrovimab)

Brief Description of Service:

Clesrovimab (also known as MK-1654) is an investigational, long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) disease in infants.² It is designed to be administered as a single dose, regardless of birth weight, and is being studied in healthy preterm, full-term, and at-risk infants to provide protection through their first RSV season. Describe the problem (why the vaccine has been developed), and the make-up of the vaccine.

Respiratory syncytial virus (RSV) causes respiratory illness among persons of all age groups. RSV is one of the most common causes of childhood illness and is the most common cause of hospitalization in infants.¹ It also causes severe disease and hospitalizations in older adults, especially those with certain chronic medical conditions. It most commonly causes a cold-like illness but can also cause lower respiratory infections, like bronchiolitis and pneumonia.

The U.S. Food and Drug Administration has approved this vaccine on June 9, 2025.³

The Advisory Committee on Immunization Practices (ACIP) recommended approval of this vaccine for infants aged 8 months and younger who are not protected by a maternal vaccine on June 30, 2025.

The CPT code for this vaccine is effective 07/01/2025.

Recommendation:

The respiratory syncytial virus (Clestrovimab) vaccine is established for infants aged 8 months and younger who are not protected by a maternal vaccine.

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

90382

Other codes (investigational, not medically necessary, etc.):

N/A

References:

1. Centers for Disease Control and Prevention. Clinical Overview of RSV. Available at <https://cdc.gov/rsv/hcp/clinical-overview/index.html>. Accessed June 2025.
2. Merck. Merck's Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants. October 2024. Available at <https://www.merck.com/news/mercks-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv-preventative-monoclonal-antibody-significantly-reduced-incidence-of-rsv-disease-and-hospitalization-in-heal/>. Accessed June 2025.
3. U.S. Food and Drug Administration. Available at <https://www.fda.gov>. Accessed June 2025.

Joint Blue Cross/BCN Medical Policy History

Policy Effective Date	Blue Cross Signature Date	BCN Signature Date	Comments
7/1/25	8/19/25		Joint policy established

Next Review Date: This is an established policy and no longer subject to periodic review

Retired